ICMR Study: Rising Toll of Drug-Resistant Superbugs
A recent study from the Indian Council of Medical Research highlights a critical healthcare crisis across tertiary hospitals in India. Specifically, the comprehensive analysis shows that drug-resistant infections lead to significantly higher mortality rates and substantially greater treatment costs than susceptible strains. Therefore, clinicians must adopt aggressive antimicrobial stewardship and rapid diagnostic strategies immediately.
The Alarming Burden of Drug-Resistant Infections
The multi-center study evaluated data from 1.6 lakh hospitalized patients across 20 tertiary-care hospitals between April 2022 and April 2025. Among these patients, 26,213 individuals developed culture-confirmed infections caused by four critical Gram-negative pathogens. These pathogens include Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Alarmingly, researchers discovered that 61.1% of these isolates exhibited resistance to carbapenems. Consequently, clinicians are losing reliable first-line and last-resort therapeutic options for severe nosocomial infections. Furthermore, these resistant strains place an enormous operational burden on critical care units.
Mortality Rates and Length of Hospital Stay
The ICMR research demonstrated higher in-hospital mortality across all four evaluated pathogen groups. For instance, mortality reached 31.2% in carbapenem-resistant Klebsiella pneumoniae cases compared to 23.5% in sensitive infections. Similarly, resistant E. coli infections caused 24.4% mortality versus 17.3% for susceptible variants.
Furthermore, resistant Acinetobacter baumannii infections showed a 37.9% mortality rate compared to 32.8% in sensitive cases. Meanwhile, resistant Pseudomonas aeruginosa led to 28.9% mortality versus 20.2% in drug-susceptible cases. Additionally, hospitalized patients with drug-resistant strains required significantly longer inpatient care. For example, resistant E. coli extended average hospital stays from 17.8 days to 23.1 days.
Escalating Treatment Costs and Clinical Implications
Drug resistance also imposes severe financial toxicity on patients and health systems. According to the study findings, antibiotic therapy costs were 1.1 to 2 times higher for drug-resistant cases. For instance, the average antibiotic expenditure for resistant E. coli reached $420 compared to $211 for susceptible infections.
In addition, treatment costs for resistant Klebsiella, Acinetobacter, and Pseudomonas reached $587, $655, and $702 per patient, respectively. Therefore, managing multidrug resistance requires costly combination therapies and specialized supportive care. In response, infectious disease experts recommend expanding molecular diagnostics to shorten turnaround times. Moreover, hospitals must enforce robust infection control practices and outpatient parenteral antimicrobial therapy where feasible.
Frequently Asked Questions
Q1: What did the ICMR study reveal about carbapenem resistance in India?
The study found that 61.1% of evaluated Gram-negative bacterial infections across 20 tertiary hospitals showed resistance to carbapenem antibiotics.
Q2: How much higher are antibiotic costs for drug-resistant infections?
Antibiotic treatment costs are 1.1 to 2 times higher for resistant infections compared to drug-susceptible strains.
Q3: Which bacterial pathogens were evaluated in the study?
The researchers evaluated four major Gram-negative bacteria: E. coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
References
- Drug-resistant infections kill more, cost more: ICMR study - ETHealthworld
- The Lancet Regional Health – Southeast Asia: Mortality and Economic Burden of Carbapenem-Resistant Pathogens in India
- Indian Council of Medical Research (ICMR) - Antimicrobial Resistance Surveillance Network (AMRSN) Reports
